Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Trending T
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending Topics
Diabetes
Clinical Development
Biologics
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
RSV
Biotech
Pfizer takes $230M hit after axing failed DMD gene therapy
Pfizer disclosed the discontinuation of a DMD gene therapy—and the financial fallout—alongside the axing of a RSV combination vaccine.
Nick Paul Taylor
Jul 30, 2024 8:15am
FDA delays decision on Moderna's RSV shot until the end of May
May 10, 2024 10:30am
Layoffs at Meissa Vaccines as biotech's future lies in limbo
Mar 5, 2024 10:25am
Investors home in on Moderna's RSV, CMV prospects
Feb 22, 2024 10:09am
CRO hVIVO reels in £16.8M clinical trial deal for RSV drug
Dec 13, 2023 11:28am
Enanta halts work on joint hMPV-RSV drug to extend cash to 2027
Nov 21, 2023 8:30am